At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 23, 2026 at 16:07 ET
Edgewise Therapeutics is holding its 2026 Annual Meeting where shareholders are asked to vote on three proposals: electing three director nominees, ratifying KPMG LLP as the independent auditor, and approving the compensation of named executive officers. The filing is a definitive proxy statement filed by the company, indicating standard, routine corporate governance matters.
- The filing is a DEFA14A, a definitive proxy statement for the 2026 Annual Meeting.
- Three proposals are on the ballot: election of directors (Laura Brege, Badreddin Edris, Jonathan Root), ratification of KPMG LLP as auditors, and an advisory vote on executive compensation.
- The company is requesting votes by June 3, 2026, for a meeting on June 4, 2026.
- The filing was made by the registrant (Edgewise Therapeutics, Inc.), not a dissident party.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access